Joining today's call from Globus Medical will be Dan Scavilla, President and CEO, and Keith Pfeil, Chief Operating Officer and Chief Financial Officer. This review is being made available via webcast, ...

1. Globus Medical’s Excelsius robotic technologies are now compatible with the Reline Open, Modular, Mass, Mass Reduction, Small Stature, Mass Midline and Reline Cervical from NuVasive, CEO Dan ...

Globus also has its own VR solution, with the Exclesius GPS Navigation Robot and the Excelsius 3D imaging system. The resulting merged company will look to combine NuVasive's distribution network with ...

Globus Medical reported its financial results for Q1 2025, revealing a miss on both earnings and revenue forecasts. The company posted an earnings per share (EPS) of $0.68, falling short of the ...

Across the recent three months, 6 analysts have shared their insights on Globus Medical GMED, expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Globus Medical Inc (Symbol: GMED) entered into oversold territory, hitting an RSI reading of ...

NEW DELHI: Globus Spirits Ltd, known for its Terai gin and Doaab single malt, is looking to expand into new categories, including beer and additional variants of single malt whisky, as part of its ...

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter.

AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, ...